This study examines whether adding brief guided mindfulness exercises to accelerated Transcranial Magnetic Stimulation (TMS) treatment can help people with depression feel better and maintain those improvements longer. Participants will already be receiving accelerated intermittent theta-burst stimulation (aiTBS) as part of their clinical care. During the breaks between TMS sessions, they will have the option to listen to short, app-based mindfulness practices using the commercially available and free Healthy Minds App. We will track whether this combined approach is practical, how easy participants find the meditations, and whether practicing mindfulness during treatment improves mood, well-being, or long-term recovery. The information gathered will help us design a larger study focused on improving the durability of TMS outcomes.

This study aims to explore the prevalence of mental health symptoms, including trauma exposure and posttraumatic stress symptoms in a postpartum population. The study also aims to collect information related to medical and mental health treatment seeking before, during, and after pregnancy as well as feedback on adaptations of future mental health interventions delivered during the postpartum period. Participation in this study includes a 35 minute online survey with questionnaires related to the study aims. Depending on survey responses, participants may be invited to complete an interview with study personnel to provide more specific insight on mental health treatments for perinatal individuals.

This study will recruit adults diagnosed with an oral potentially malignant disorder (OPMD). The purpose of this research study is to collect blood, saliva, and tissue samples to determine whether certain measurable characteristics (biomarkers) can be identified which may provide insight into the risk of developing cancer. Participation in this study is expected to last approximately 3 years.

Co-occurring post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) disproportionately affects Veterans and has significant negative impacts on the safety, wellbeing, and quality of life of Veterans, their romantic partners, and their families. However, treatments that address co-occurring PTSD-AUD and restore Veterans' psychosocial functioning are lacking. The overall goal of this project is to improve treatment approaches aimed at reducing symptoms of co-occurring PTSD-AUD and improving functioning among Veterans and their partners. We plan to do this by learning from Veterans, family members, and treatment providers in order to inform an adaptation of a brief dyadic AUD intervention to be delivered alongside integrated PTSD-AUD treatment for Veteran couples and then conducting a pilot trial of an adapted Brief Family Involved Treatment (B-FIT) intervention with Veterans with PTSD-AUD and their romantic partners.

This study is for patients that have been diagnosed with non-small cell lung cancer (NSCLC). This study is testing an investigational drug called Amivantamab. "Investigational" means that is not been approved by United States Food and Drug Administration (FDA). There will be no randomization in this study. Participants will be assigned to treatment upon enrollment based on disease treatment status. The primary purpose of this study is to understand how well the study treatment works and the safety of the combination of Amivantamab and Lazertinib in participants who have NSCLC with a specific eGFR mutation. Amivantamab can be given under the skin (subcutaneous) or by infusion (IV). Participants can be in the study for up to 36 months depending on how the participants disease responds to treatment.

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.

Half of cancer caregivers in the US are young adults (YA) (age 18-35) caring for a parent with advanced cancer. This presents communication and quality of life challenges for both the young adult child caregiver and parent with cancer; however, this dyad (e.g., two people together) has not been well studied. We will conduct interviews with young adult child caregivers and parents with cancer to learn more about communication challenges and support needs in this dyad. Dyad members will also complete self-report measures asking about mood, coping, communication and quality of life. Findings will inform the development of an intervention to improve dyadic communication and quality of life.

This study is for patients who have completed curative-intent treatment for colorectal cancer. It is testing an educational website called Current Together After Cancer (CTAC) to see if it improves follow-up care, including knowledge about cancer recurrence, recommended tests, and self-management of health. Participants will be randomly assigned to one of two versions of the website, with or without additional features for engaging a support person, and can use it on a computer, tablet, or smartphone. The study will last up to 16 months, including website use, surveys, and optional interviews, with participation completely voluntary. The goal is to determine whether CTAC helps patients better understand follow-up care and engage their supporters to improve adherence to recommended surveillance. There will be a total of 21 patients enrolled locally over the course of 36 months.

This is a 24-week-long treatment study for people with Alcohol Use Disorder who want to stop or cut down their drinking. The purpose of this study is to determine whether an investigational medication, APL-18881, affects craving for alcohol and/or alcohol drinking while taking the study drug. Participants will be randomly assigned to APL-18881 or a matched placebo

The goal of this observational study is to collect long-term safety and performance data for the use of the EndoForce System for connecting a hemodialysis graft to a vein in patients with End Stage Renal Disease. This is not an experimental procedure or an experimental therapy. This means that the study device has been approved by the FDA.